Article Text

PDF

Recombinant interferon alfa-2b treatment in chronic non-A, non-B/type C hepatitis.
  1. V De Conca,
  2. S Mesiti,
  3. E Vallarino,
  4. A Mornese,
  5. M Dodero
  1. EO Ospedali Galliera, Genova, Italy.

    Abstract

    In a study of 60 patients with non-A, non-B/type C (NANB/C) chronic hepatitis alanine aminotransferase (ALT) activities returned to normal after treatment with interferon alfa-2b (3 million units for six months) in 70.7% and 29.3% did not respond. The response was maintained during four to six months, follow up in 41.4% of patients. Liver biopsy specimen showed histological improvement in all patients surveyed. Treatment was well tolerated with only mild side effects.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.